Phase I Evaluation of Sodium Stibogluconate [VQD 001; VioQuest Pharmaceuticals] in Combination With Interferon alpha-2b for Solid Tumors, Lymphoma or Myeloma.

Trial Profile

Phase I Evaluation of Sodium Stibogluconate [VQD 001; VioQuest Pharmaceuticals] in Combination With Interferon alpha-2b for Solid Tumors, Lymphoma or Myeloma.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Sep 2016

At a glance

  • Drugs Interferon alpha-2b; Sodium stibogluconate
  • Indications Lymphoma; Multiple myeloma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Nov 2009 Planned number of patients changed from 24 to 54 as reported by M.D. Anderson Cancer Center record.
    • 30 Jun 2009 Trial phase changed from I/II to I and additional lead trial centre as reported by ClinicalTrials.gov.
    • 11 Jun 2008 Status changed from in progress to completed as reported by VioQuest Pharmaceuticals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top